BiotechTubeBiotechTube
Home/Immutep/Frédéric Triebel
FT

Frédéric Triebel

Chief Scientific Officer & Executive Director

Immutep

Therapeutic Areas

OncologyAutoimmune Diseases

Immutep Pipeline

DrugIndicationPhase
Eftilagimod alfa (efti)1st & 2nd line Non-Small Cell Lung Cancer (NSCLC)Phase 2/3
IMP761Autoimmune DiseasesPhase 1 (planned)
IMP731Ulcerative ColitisPhase 2
LAG525 (ieramilimab)Various cancers (Novartis partnership)Multiple Phases
Novel Small Molecule LAG-3 InhibitorOncologyEarly Research

Leadership Team at Immutep

MV
Marc Voigt
Chief Executive Officer & Executive Director
DM
Deanne Miller
Chief Operating Officer, General Counsel & Company Secretary
CM
Christian Mueller
Chief Development Officer
View full Immutep profile